To examine the disease-specific survival(DSS) after checkpoint inhibitor(CPI) therapy based on FGFR alterations and FGFR mRNA expression levels in patients with metastatic urothelial cancer(mUCa) within a multi-center cohort.
Charles Ryan: Hello, Chuck Ryan here from The University of Minnesota, and I am joined here by Dr. Elisabeth Heath, who is a friend and colleague, and she is an Associate Center Director for Translational Sciences and the Hartmann Endowed Chair for Prostate Cancer Research and a Professor of Oncology at the Karmanos Institute in […]
Introduction In spite of the rapid progress and many exciting advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the past few years, the disease remains incurable with a median overall survival of 12-35 months.1-4 Targeting the immune system to expand treatment options in the advanced disease state has resulted in significant improvements […]
Ashish Kamat: Hello, and welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat, Professor of Urology and Cancer Research at MD Anderson Cancer Center. And it’s my distinct pleasure to introduce and welcome today, Dr. Svetlana Avulova from the Mayo Clinic who is joining us today to talk about the award that she […]
Phillip Koo: Hello, my name is Phillip Koo. Welcome to Uro Today. Today we’re very honored to have with us, Evan Yu, who’s a GI medical oncologist and Professor of Medicine at the University of Washington. So today we’re going to be talking about the new term that we’ve been hearing a lot about phenotypic […]
Survivorship in bladder cancer has improved in terms of lower morbidity, mortality, and improved oncological outcomes. However, there is a dearth of research on women’s quality of life, specifically, on the effect of radical cystectomy on women’s sexual function and sexual experience.
Radiation therapy (RT) is used in the management of several cancers; however, tumor radioresistance remains a challenge. Polymorphonuclear neutrophils (PMNs) are recruited to the tumor immune microenvironment (TIME) post-RT and can facilitate tumor progression by forming neutrophil extracellular traps (NETs).
Diverse subtypes of renal cell carcinomas (RCCs) display a wide spectrum of histomorphologies, proteogenomic alterations, immune cell infiltration patterns, and clinical behavior. Delineating the cells of origin for different RCC subtypes will provide mechanistic insights into their diverse pathobiology.
The clear cell renal cell carcinoma (ccRCC) is the main pathological subtype of renal cell carcinoma. Immune system evasion, one hallmark of cancer, contributes to cancer cells in escaping from the attack of immune cells.
The impact of MRI-lesion targeted (TB) and systematic biopsy (SB) Gleason score (GS) as a predictor for final pathological GS still remains unclear. All patients with TB + SB, and subsequent radical prostatectomy (RP) between 01/2014-12/2020 were analyzed.
